Biogen (BIIB) PT Lowered to $200 at Barclays
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $212.55 +1.63%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $200.00 (from $215.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $42 at Mizuho
- Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
